Chronic Obstructive Pulmonary Disease (COPD) Market to Reach USD 28.4 Billion by 2032

According to analysts at Vantage Market Research, the Global Chronic Obstructive Pulmonary Disease (COPD) Market size is worth USD 18.2 Billion in 2023 and is projected to reach USD 28.4 Billion by 2032, growing at a CAGR (Compound Annual Growth Rate) of 4.9% from 2024 to 2032. The Market is driven by growing elderly population, advancements in treatment options, increasing air pollution, and enhanced patient awareness of early diagnosis and care.

Market Overview

Chronic obstructive pulmonary disease (COPD) is a long-term respiratory disease that causes breathing difficulties, coughing, wheezing, and other symptoms. The disease is frequently triggered by prolonged exposure to irritants such as cigarette smoke, air pollution, and dust. According to the World Health Organization (WHO), COPD ranks as the third leading cause of death worldwide and is projected to become the fifth leading cause of death by 2030. The prevalence of COPD is increasing worldwide, particularly in developing countries with high smoking rates, and air pollution is a significant problem. 

Increasing collaboration among key players in the Chronic Obstructive Pulmonary Disease (COPD) market is shaping the landscape of research, development, and patient care. Pharmaceutical companies, healthcare providers, and research institutions are forming strategic partnerships to leverage their combined expertise and resources. These collaborations facilitate the sharing of knowledge and best practices, driving innovation in treatment options and enhancing the development of novel therapies.

AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of Breztri to improve cardiopulmonary outcomes in people with COPD

• In March 2024, AstraZeneca has announced the launch of a Phase III trial to explore the potential impact of its triple-combination inhaled therapy, Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate, or BGF), on severe cardiopulmonary outcomes, including mortality, in individuals with chronic obstructive pulmonary disease (COPD) who face heightened cardiopulmonary risk, regardless of their history of exacerbations

Key Takeaways from the Report

• In 2023, North America dominated the market with 38.60% market share. In region, market is driven by presence of  largest pharmaceutical companies researching and developing innovative drugs and devices for COPD treatment
• By Drug class, Bronchodilators is accounted 32.60% market share. The occurrence and impact of such symptoms among COPD populations has led bronchodilators to become a primary therapeutic option
• Based on route of administration, the Inhalation segment is dominated the market with 51.30% market share. Inhaled therapies bypass the digestive system, allowing for a much quicker onset of therapeutic effects compared to oral medications
• Based on distribution channel, the Wearable segment is dominated the market with 36.20% market share

Top Companies

• Astrazeneca
• Alkem
• Mylan N.V.
• Novartis AG
• F.Hoffman-La Roche Ltd
• Genentech Inc
• Theravance Biopharma
• Sunovion Pharmacuticals Inc
• Sanofi
• Verona Pharmaceuticals

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

• In September 2024, The U.S. Food and Drug Administration (FDA) has granted approval for Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) exhibiting an eosinophilic phenotype. This makes Dupixent the first biologic medication approved in the U.S. specifically for these patients